Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
3179.00    95.00 (3.08%)
Bid:
3186.00
Ask:
3188.00
Spread: 2.00 (0.063%)
Market Cap: £4.43b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Acquisition

24 May 2013 07:00

RNS Number : 4809F
Croda International PLC
24 May 2013
 



24 May 2013

 

Croda International Plc

 

Acquisition ofSpecialty Products Business from Arizona Chemical

Naturally derived polyamides expand Croda's broad portfolio of effects

 

Croda International Plc announces today that it has completed the acquisition of the Specialty Products business of Arizona Chemical based in Jacksonville, Florida in the USA. 

 

The acquisition adds a portfolio of class leading oil gelling polymers to Croda's business and further expands its footprint in the polymers arena, while strengthening Croda's leading position in speciality chemicals derived from renewable resources. The technologies and products of the acquired business are naturally derived polyamides with high bio-renewable content, covered by a range of patents.

 

Keith Layden, Croda's Chief Technology Officer, said:

 

"This acquisition represents further progress in our strategy to acquire complementary new technologies. The varied functionality of these specialised polyamides will be a valuable addition to our offerings across both the Consumer Care and Performance Technologies market sectors. In addition, there are a number of opportunities to further differentiate the technology and create value for ourselves and our customers."

 

No manufacturing assets will be acquired as part of this transaction and Croda will immediately commence the relocation of the products to Croda's Mevisa manufacturing site in Spain and when ready, re-launch the products with new trade names and marketing identities.

 

For further information please contact:

 

Keith Layden, Chief Technology Officer Tel: 01405 860 551

Sean Christie, Group Finance Director

 

Charles Armitstead / Rosie Oddy, Pendomer Communications Tel: 020 3603 5224 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQAJMATMBJTBFJ
Date   Source Headline
11th Jun 20262:58 pmRNSDirector/PDMR Shareholding
11th Jun 20269:15 amRNSDirector Declaration
1st Jun 20261:46 pmRNSDirector/PDMR Shareholding
29th May 20264:06 pmRNSDirector/PDMR Shareholding
29th May 20263:10 pmRNSDirector/PDMR Shareholding
29th May 20261:53 pmRNSDirector/PDMR Shareholding
29th May 20261:52 pmRNSDirector/PDMR Shareholding
29th May 20261:45 pmRNSDirector/PDMR Shareholding
15th May 20269:23 amRNSDirector/PDMR Shareholding
12th May 202612:10 pmRNSDirector/PDMR Shareholding
6th May 20261:21 pmRNSDirector/PDMR Shareholding
23rd Apr 202611:20 amRNSResult of AGM
22nd Apr 20267:00 amRNSFirst quarter 2026 sales in line with expectations
13th Apr 20261:41 pmRNSDirector/PDMR Shareholding
31st Mar 202611:48 amRNSHolding(s) in Company
26th Mar 20264:34 pmRNSDirector/PDMR Shareholding
18th Mar 20263:31 pmRNSDirector/PDMR Shareholding
18th Mar 20263:30 pmRNSDirector/PDMR Shareholding
18th Mar 20263:27 pmRNSDirector/PDMR Shareholding
18th Mar 20263:25 pmRNSDirector/PDMR Shareholding
18th Mar 20263:23 pmRNSDirector/PDMR Shareholding
18th Mar 20263:23 pmRNSDirector/PDMR Shareholding
18th Mar 20263:20 pmRNSDirector/PDMR Shareholding
16th Mar 20261:36 pmRNSAnnual Financial Report
16th Mar 20261:36 pmRNSAnnual Financial Report
11th Mar 202611:28 amRNSDirector/PDMR Shareholding
11th Mar 202611:28 amRNSDirector/PDMR Shareholding
6th Mar 20261:32 pmRNSDirector/PDMR Shareholding
3rd Mar 20265:13 pmRNSHolding(s) in Company
24th Feb 20267:00 amRNSResults for the year ended 31 December 2025
11th Feb 20262:59 pmRNSDirector/PDMR Shareholding
13th Jan 20262:47 pmRNSDirector/PDMR Shareholding
9th Jan 20267:00 amRNSDirector Declaration
11th Dec 202511:30 amRNSDirector/PDMR Shareholding
11th Nov 202511:19 amRNSDirector/PDMR Shareholding
16th Oct 20257:00 amRNSThird quarter 2025 sales update
14th Oct 20251:58 pmRNSDirector/PDMR Shareholding
8th Oct 20254:26 pmRNSDirector/PDMR Shareholding
1st Oct 20253:45 pmRNSDirector/PDMR Shareholding
18th Sep 20253:49 pmRNSHolding(s) in Company
12th Sep 202510:11 amRNSDirector/PDMR Shareholding
11th Sep 20253:54 pmRNSDirector/PDMR Shareholding
29th Aug 20253:58 pmRNSHolding(s) in Company
29th Aug 202511:03 amRNSHolding(s) in Company
27th Aug 20251:58 pmRNSHolding(s) in Company
22nd Aug 20254:24 pmRNSDirector/PDMR Shareholding
22nd Aug 202511:55 amRNSDirector/PDMR Shareholding
14th Aug 20259:10 amRNSDirector/PDMR Shareholding
12th Aug 202511:42 amRNSDirector/PDMR Shareholding
7th Aug 20259:16 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.